A Randomized, Double-blind, Placebo-controlled Phase I/IIa Study in Patients With Abdominal or Perianal Fistulizing Crohn's Disease to Explore the Safety, Tolerability and Preliminary Efficacy of Locally Administered DLX105.
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2014
At a glance
- Drugs DLX 105 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- 03 Feb 2014 Status changed from recruiting to completed as reported by Clinical Trials.gov record.
- 26 Jun 2012 New trial record